ArticleBMC gastroenterology2016
Management of Helicobacter pylori infections.
Article in BMC gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Comparison of concomitant therapy versus standard triple-drug therapy for eradication of Helicobacter pylori infection: A prospective open-label randomized controlled trial.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2019Trial
- Eradication efficacy of empiric bismuth quadruple therapy containing amoxicillin in the first-line treatment of Helicobacter pylori in Ningxia, China.BMC gastroenterology · 2026Article
- Comparative effectiveness of genotype-guided and empirical bismuth-containing quadruple therapy forFrontiers in pharmacology · 2026Article
- Clinically apparent Helicobacter pylori infection and the risk of incident Alzheimer's disease: A population-based nested case-control study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- The Burden and Risk Factors ofResearch and reports in tropical medicine · 2024Article
- Application of artificial intelligence in endoscopic image analysis for the diagnosis of a gastric cancer pathogen-Helicobacter pylori infection.Scientific reports · 2023Article
- Frequency and seasonality of viableItalian journal of food safety · 2023Article
- Helicobacter pylori infection.Nature reviews. Disease primers · 2023Review
- Extraction of antibacterial peptides againstArchives of medical science : AMS · 2022Article
- The metabolomic analysis of fiveRSC advances · 2021Article
- The Protective Effects of Helicobacter pylori Infection on Allergic Asthma.International archives of allergy and immunology · 2021Review
- Development and Validation of Multiplex Quantitative PCR Assay for Detection ofInfection and drug resistance · 2021Article
- Putative determinants of virulence inVirulence · 2020Article
- From genes polymorphisms to mucosal expression of cytokines: evaluating IL-23/IL-17 axis in adult patients with gastritis.African health sciences · 2020Article
- Novel virulence factorWorld journal of gastroenterology · 2020Review
- Vying for the control of inflammasomes: The cytosolic frontier of enteric bacterial pathogen-host interactions.Cellular microbiology · 2020Review
- Diagnosis and treatment ofChronic diseases and translational medicine · 2019Review
- Pathogenesis and clinical management ofWorld journal of gastroenterology · 2019Review
- Role of the brain-gut axis in gastrointestinal cancer.World journal of clinical cases · 2019Review
- Comparison between the two drug regimens of PPI+Amoxicillin+ Rifampicin and PPI+Amoxicillin+ Levofloxacin for the treatment ofGastroenterology and hepatology from bed to bench · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfection with Helicobacter pylori is associated with severe digestive diseases including chronic gastritis, peptic ulcer disease, and gastric cancer. Successful eradication of this common gastric pathogen in individual patients is known to prevent the occurrence of peptic ulcer disease and gastric cancer. DISCUSSION: With half of the world's population being infected with H, pylori and only few antibiotics result in an effective eradication, a successful antibiotic driven worldwide eradication program seems unlikely. In addition, H. pylori eradication is not always beneficial as it has been described that eradication can be associated with an increased frequency of other disorders such as pediatric asthma, inflammatory bowel diseases and Barrett's Esophagus. We have to accept that eradication of this infection is a two-edged sword that is both useful and harmful and we should therefore focus our H. pylori eradication policy toward selectively identify and destroy only the virulent strains.
conclusionIn order to still be able to effectively treat H. pylori infections in the future we need an alternative diagnostic/treatment algorithm. This would involve a shift towards more precise and enhanced disease predicting diagnosis that tries to identify patients with chance of developing severe diseases such as gastric cancer, rather than the current regime that is geared towards find and destroy all H. pylori.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.